Sacituzumab tirumotecan extended median overall survival to 19.0 months versus 12.1 months with physician’s choice of chemotherapy in previously treated advanced or recurrent endometrial cancer, according to results from the phase 3 TroFuse-005 trial published in The Lancet.
The international, open-label study randomized 776 patients at 242 sites across 31 countries to receive sacituzumab tirumotecan (sac-TMT) or treatment of physician’s choice (TPC) — doxorubicin 60 mg/m² every three weeks or paclitaxel 80 mg/m² on days 1, 8, and 15 of a 28-day cycle.
All patients had received prior platinum-based chemotherapy and anti–PD-1/PD-L1 therapy, with up to three prior lines of treatment allowed. The dual primary endpoints were progression-free survival (PFS) by blinded independent central review and overall survival (OS) in the intention-to-treat population.
Sac-TMT was administered intravenously at 4 mg/kg on days 1 and 15 of each 28-day cycle. Crossover was prohibited. Median follow-up was 14.0 months.
PFS events occurred in 271 patients receiving sac-TMT and 285 receiving TPC, yielding a hazard ratio of 0.59 (P < .0001). Median PFS was 7.2 months versus 3.9 months; the estimated 12-month PFS rate was 29% versus 12%.

OS favored sac-TMT with a hazard ratio of 0.68 (P = .0001). Deaths occurred in 157 patients (41%) in the sac-TMT arm and 204 (52%) in the TPC arm. Estimated 12-month OS was 63% versus 51%.
The objective response rate was 35.1% with sac-TMT versus 17.3% with TPC (P < .0001). Median duration of response was 11.1 months versus 6.9 months, respectively.
Grade 3 or higher adverse events occurred in 69% of sac-TMT recipients versus 57% with TPC. Adverse events led to death in 3% versus 2%. Stomatitis (57% vs 17%) and ocular surface toxicity (30% vs 7%) were more frequent with sac-TMT.
In the sac-TMT arm, 97.1% of patients experienced treatment-related adverse events compared with 89.6% in the physician’s choice arm; grade 3 or higher events affected 54.4% and 41.4% respectively, with anemia the most frequent grade 3 or higher treatment-related adverse event (20.8% vs 13.4%). Treatment-related adverse events led to death in 0.8% of patients in each arm. Global health status and quality of life was maintained over time in both treatment arms.
The open-label design contributed to uneven pretreatment dropout: 23 of 390 patients in the TPC group versus 2 of 386 in the sac-TMT group did not receive assigned treatment. Patients had varied prior treatment histories, and the trial was not structured to evaluate how earlier regimens influenced sensitivity. Subgroup analyses were exploratory, and treatment acceptability was not directly assessed.
Merck Sharp & Dohme funded the study and participated in its design, analysis, and reporting. Three authors are company employees and may hold stock; many others reported institutional funding and personal fees from industry.
“These findings support sac-TMT as a new standard-of-care systemic therapy for this patient population with few effective therapeutic alternatives,” wrote the study authors led by Domenica Lorusso, MD, PhD, of Humanitas University in Milan, and Bhavana Pothuri, MD, of NYU Grossman School of Medicine.
“Antibody-drug conjugates such as sacituzumab tirumotecan are effective in targeting and treating these aggressive cancers to delay its progression and prolong survival when it recurs,” said Dr. Lightfoot.
“As a result of this practice-changing study, clinical guidelines for endometrial cancer will need to be reassessed to incorporate sacituzumab tirumotecan,” Pothuri added.
The study was presented at the ESMO Congress 2026 (Abstract LBA11) and simultaneously published online in The Lancet on October 26, 2026.
Keep reading